Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HENOCK SAINT JACQUES

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1144207275
CMS profile
324326
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$28,928.70

135 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 135 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HENOCK SAINT JACQUES

NPI 1144207275 · CMS profile ID 324326

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 135 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144207275?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HENOCK SAINT JACQUES, NPI 1144207275, CMS profile ID 324326. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 135 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144207275?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HENOCK SAINT JACQUES, NPI 1144207275, CMS profile ID 324326. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 135 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144207275?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HENOCK SAINT JACQUES, NPI 1144207275, CMS profile ID 324326, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 135 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1144207275?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

135 matching records · $28,928.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 135 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 135.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Azurity Pharmaceuticals, Inc. $15.5308/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134012065 CMS
Corcept Therapeutics $31.0208/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117783925 CMS
SCPHARMACEUTICALS INC. $26.4407/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132290977 CMS
Novartis Pharmaceuticals Corporation $21.3007/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087296129 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $32.3907/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117888319 CMS
Corcept Therapeutics $22.2507/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117783905 CMS
Novartis Pharmaceuticals Corporation $31.2407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087296133 CMS
SCPHARMACEUTICALS INC. $139.6507/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132289693 CMS
SCPHARMACEUTICALS INC. $2,800.0007/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132289698 CMS
Novo Nordisk Inc $15.6707/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097137038 CMS
SCPHARMACEUTICALS INC. $14.0907/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132288891 CMS
Esperion Therapeutics, Inc. $24.2407/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129453516 CMS
Esperion Therapeutics, Inc. $3.4507/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129453512 CMS
Esperion Therapeutics, Inc. $0.9107/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129453514 CMS
Abbott Laboratories $124.1807/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124864734 CMS
SCPHARMACEUTICALS INC. $26.5107/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132285571 CMS
Merck Sharp & Dohme LLC $22.6807/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141905046 CMS
E.R. Squibb & Sons, L.L.C. $15.9606/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101764913 CMS
Novartis Pharmaceuticals Corporation $24.9606/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087296123 CMS
Amgen Inc. $23.6606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111695784 CMS
Corcept Therapeutics $22.6906/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117783901 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $30.2206/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117888317 CMS
E.R. Squibb & Sons, L.L.C. $18.2306/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101764916 CMS
E.R. Squibb & Sons, L.L.C. $3.2706/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101764920 CMS
SCPHARMACEUTICALS INC. $149.2606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132282990 CMS
SCPHARMACEUTICALS INC. $2,800.0006/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132283001 CMS
Esperion Therapeutics, Inc. $124.8306/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129453510 CMS
Novartis Pharmaceuticals Corporation $24.6706/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087296115 CMS
Bayer Healthcare Pharmaceuticals Inc. $30.8706/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086106924 CMS
Novartis Pharmaceuticals Corporation $24.8906/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087296113 CMS
SCPHARMACEUTICALS INC. $19.3805/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132278905 CMS
Merck Sharp & Dohme LLC $3,815.0005/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141908408 CMS
Xeris Pharmaceuticals, Inc. $137.5005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144596380 CMS
Corcept Therapeutics $111.0505/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117783937 CMS
E.R. Squibb & Sons, L.L.C. $25.6705/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101764902 CMS
Merck Sharp & Dohme LLC $150.0005/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141817371 CMS
Novartis Pharmaceuticals Corporation $19.7805/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087296063 CMS
SCPHARMACEUTICALS INC. $13.2205/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132274729 CMS
Amgen Inc. $24.8605/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111695782 CMS
Merck Sharp & Dohme LLC $1,146.0905/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141817373 CMS
Merck Sharp & Dohme LLC $82.2105/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141948464 CMS
SCPHARMACEUTICALS INC. $19.1905/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132273167 CMS
Lumenis BE inc $672.6905/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1082155512 CMS
Esperion Therapeutics, Inc. $19.3905/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129453508 CMS
Corcept Therapeutics $8.0005/01/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117783955 CMS
SCPHARMACEUTICALS INC. $19.4504/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132272028 CMS
SCPHARMACEUTICALS INC. $1,050.0004/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132272033 CMS
E.R. Squibb & Sons, L.L.C. $41.2904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101764894 CMS
Azurity Pharmaceuticals, Inc. $27.6104/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134012063 CMS
AstraZeneca Pharmaceuticals LP $21.8004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105646212 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,697.22 110
PY2020 $5,592.92 76
PY2021 $3,381.33 86
PY2022 $2,201.03 84
PY2023 $47,455.70 151
PY2024 $28,928.70 135
PY2025 $18,215.04 125

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $191,275.61 29
PY2024 Principal investigator $138,500.00 3
PY2022 Principal investigator $2,125.00 1
PY2021 Principal investigator $22,977.77 36
PY2020 Recipient $300.00 1
PY2020 Principal investigator $36,457.23 47
PY2019 Principal investigator $105,425.88 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 12/25/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695379
Principal investigator 1 Boehringer Ingelheim International GmbH $21.75 12/25/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695381
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 12/25/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695383
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 12/17/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695389
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 12/17/2025 Non-covered Recipient Entity
Harlem Cardiology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220773811
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Harlem Cardiology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220773813
Principal investigator 1 Boehringer Ingelheim International GmbH $3,276.00 12/12/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695373
Principal investigator 1 Boehringer Ingelheim International GmbH $2,822.00 12/12/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695375
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 12/12/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695377
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/04/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996568
Principal investigator 1 Boehringer Ingelheim International GmbH $2,534.00 11/19/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695371
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695387
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 10/27/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695385
Principal investigator 1 Boehringer Ingelheim International GmbH $1,896.00 10/20/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695367
Principal investigator 1 Boehringer Ingelheim International GmbH $198.00 10/20/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695369
Principal investigator 1 Boehringer Ingelheim International GmbH $3,276.00 10/02/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695361
Principal investigator 1 Boehringer Ingelheim International GmbH $2,822.00 10/02/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695363
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 10/02/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695365
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 09/30/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996564
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 09/24/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695357
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 09/24/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695359
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 08/26/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695355
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 08/12/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996562
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 07/28/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695349
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 07/28/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695351
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220695353
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 06/20/2025 Non-covered Recipient Entity
The Mount Sinai Doctors Faculty Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996566
Principal investigator 1 Amgen Inc. $18,401.93 01/27/2025 Non-covered Recipient Entity
HARLEM CARDIO
The African American Heart Study: A Real-World Data Study of Atherosclerotic Cardiovascular Risk in African American and Black Participants in the US No dispute reported 06/30/2026 1246642061
Principal investigator 1 Amgen Inc. $140,375.00 01/22/2025 Non-covered Recipient Entity
ACCUHEALTH TECHNOLOGIES INC
The African American Heart Study: A Real-World Data Study of Atherosclerotic Cardiovascular Risk in African American and Black Participants in the US No dispute reported 06/30/2026 1246638722